HUTCHMED (China) Limited
Market Cap
$2.58B
P/E Ratio
5.40
EPS
$2.65
Dividend Yield
0.00%
52-Week Range
$11.51 — $19.50
Volume
3.81K
Avg Volume
37.48K
Beta
0.51
P/E (TTM)
5.40
Forward P/E
46.05
PEG Ratio
0.06
P/S (TTM)
4.01
P/B (TTM)
2.00
P/FCF
-63.87
EV/EBITDA
1039.07x
EV/Sales
—
ROE (TTM)
0.47%
ROA (TTM)
0.26%
ROIC
-0.00%
Gross Margin
0.09%
Operating Margin
-0.03%
Net Margin
1.64%
Debt/Equity
0.08
Current Ratio
4.65
EPS Growth (YoY)
+16.33%
Revenue Growth (YoY)
-0.11%
EPS Growth (3Y)
-0.02%
EPS Growth (5Y)
-0.06%
Sales Growth (3Y)
+0.30%
Sales Growth (5Y)
+0.32%
EPS Est (This Year)
$0.31
EPS Est (Next Year)
$0.46
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$1.56
Sell
1 = Strong Buy, 5 = Strong Sell
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
180.60M
Float
170.46M
Free Float %
94.39%
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
HK
Exchange
NASDAQ
IPO Date
2016-03-16
Employees
1811
CEO
Chig Fung Cheng
Index Membership
—
Website
https://www.hutch-med.com
HUTCHMED (China) Limited (HCM) is a healthcare company in the drug manufacturers - specialty & generic industry listed on the NASDAQ. With a market capitalization of $2.58B, a P/E ratio of 5.40, HCM is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare HCM against other stocks using dozens of fundamental and technical filters.
HUTCHMED (China) Limited (HCM) has a trailing twelve-month (TTM) P/E ratio of 5.40. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, HUTCHMED (China) Limited (HCM) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
HUTCHMED (China) Limited (HCM) has a market capitalization of $2.58 billion, classifying it as a mid-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Sell" rating on HUTCHMED (China) Limited (HCM) with an average score of 4.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $17.50 implies 22.4% upside from the current price.